胃癌中P-糖蛋白、多药耐药相关蛋白、肺耐药蛋白的表达及其意义

 目的　检测胃癌组织中P-糖蛋白（P-gp）、多药耐药相关蛋白（MRP）、肺耐药蛋白（LRP）的表达，分析其与胃癌临床病理因素的关系。方法　采用免疫组织化学SP法对59例胃癌患者癌组织进行研究。结果　在59例胃癌患者中P-gp阳性率最高[86.4 %（51例）]，其次为LRP[84.7 %（50例）]，二者呈正相关（r＝0.803）；MRP阳性率最低[27.1 %（16例）]。P-gp、MRP、LRP与分化程度无关（均P＞0.05）。P-gp与临床分期呈正相关（r＝0.742），MRP、LRP均与胃癌浸润深度、淋巴结转移与否及分化程度无关。结论　P-gp、MRP、LRP在未接受化疗胃癌组织中高表达，提示胃癌中存在P-gp、MRP、LRP介导的原发性耐药。

Expression and significance of P-gp, LRP, MRP in gastric cancer

Objective To detect the expression of multidrug resistance proteins P-gp, LRP, MRP, and analyze the relationship between them and the clinicopathological factors. Methods The expression of P-gp,LRP, MRP in formalin-fixed paraffin-embedded tissue sections was determined by a labelled StreptavidinPeroxidase (SP) immunohistochemical technique, and the results were analyzed in correlation with clinicopathological data. None of these patients received chemotherapy prior to surgery. Results The positive rates of P-gp, LRP, MRP were 86.4 %, 84.7 % and 27.1%, respectively. The difference between the positive rate of P-gp and MRP was significant statistically, as well as the difference between the expression of MRP and LRP. No significant difference was observed between P-gp and LRP, but the positively correlation between the expression of P-gp and LRP was observed. No significant correlation between the expression of P-gp, LRP, MRP and the grade of differentiation were observed. The expression of P-gp was correlated with clinical stages positively (r=0.742), but the difference with the expression of P-gp in different stages was not significant. Conclusion The expression of P-gp, LRP, MRP in patients with gastric cancer without prior chemotherapy are high and indicates that innate drug resistance may exist in gastric cancer.